Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

BACKGROUND: The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chron...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Pierangeli, Giulia, Lovati, Carlo, Aguggia, Marco, d’Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Rao, Renata, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091153/
https://www.ncbi.nlm.nih.gov/pubmed/33941080
http://dx.doi.org/10.1186/s10194-021-01247-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091153/
https://www.ncbi.nlm.nih.gov/pubmed/33941080
http://dx.doi.org/10.1186/s10194-021-01247-1

Ejemplares similares